Nektar Therapeutics Launches Phase 3 Trials for Rezpegaldesleukin in Atopic Dermatitis
Event summary
- Nektar Therapeutics initiated Phase 3 trials for rezpegaldesleukin in moderate-to-severe atopic dermatitis, targeting 1,530 patients across three global studies.
- The ZENITH AD program includes two trials for treatment-naive patients and one for treatment-experienced patients, with topline data expected mid-2028.
- Rezpegaldesleukin is a first-in-class regulatory T-cell biologic designed to restore immune balance in autoimmune disorders.
- Nektar plans to initiate a Phase 3 trial for alopecia areata in early 2027 and expects Type 1 diabetes data in 2027.
The big picture
Nektar Therapeutics is advancing its lead candidate, rezpegaldesleukin, through Phase 3 trials in atopic dermatitis, aiming to address a significant unmet need in immune-mediated diseases. The company's strategy hinges on leveraging the drug's novel mechanism targeting regulatory T-cells, which could differentiate it in a competitive biologic landscape. Success in these trials would position Nektar as a key player in autoimmune therapies, with potential applications across multiple indications.
What we're watching
- Clinical Efficacy
- Whether rezpegaldesleukin can demonstrate sustained efficacy and safety in Phase 3 trials to support regulatory approval.
- Market Differentiation
- How Nektar positions rezpegaldesleukin against existing treatments for atopic dermatitis and alopecia areata.
- Pipeline Expansion
- The pace at which Nektar advances rezpegaldesleukin into other autoimmune indications like Type 1 diabetes.
Related topics